Company intelligence / Profile preview

Alvea Holdings

Cambridge, Massachusetts, United Statesreaganudall.org ↗

Ownership: Private
Development stage: Phase 1

Overview

Alvea developed a DNA vaccine candidate (Alveavax-v1.2) against the Omicron variant of COVID-19 and became the fastest startup to take a new drug into Phase 1 clinical trials (196 days from founding to first patient dosing). However, early efficacy results were underwhelming, and the company ultimately decided to wind down operations[2][3][5].

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccines
Industry: Biotech

Drug pipeline

2 assets

alveavax

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Alvea Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alvea Holdings.

Explore the full profile